Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PHILADELPHIA, June 6, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Merit Medical Systems, Inc. ("Merit Medical" or the "Company") (Nasdaq: MMSI) on behalf of the Company's stockholders. Recently a shareholder class action complaint was filed in federal court on...

Kaskela Law LLC Announces Investigation of Merit Medical Systems, Inc. (MMSI) and Encourages Long-Term MMSI Investors to Contact the Firm

Starboard Value, a top-tier activist investor firm, amassed a 9% stake in Merit Medical Systems, Inc. (NASDAQ: MMSI), a manufacturer of disposable medical devices, CNBC reported.

Activist Starboard Value targets medical device company

A successful activist is gently pushing for change at Merit Medical Systems.

Activist Starboard pushes for change at a medical device company that could be a takeover candidate

Nominates Three Medical Device Industry Veterans – Lonny Carpenter, David Floyd    and James Hogan – for Election to the Board of Directors

Merit Medical Announces Agreement With Starboard

SOUTH JORDAN, Utah, May  26, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it received the CE mark for the WRAPSODY™ Endovascular Stent Graft System from the British Standards Institution (BSI). The WRAPSODY system is a flexible self-expanding endoprosthesis indicated for use in hemodialysis patients for the treatment of stenosis or occlusion within central veins as well as the dialysis outflow circuit of an arteriovenous (AV) fistula or AV graft.

Merit Medical Receives CE Mark for Wrapsody™ Endovascular Stent Graft System

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock?

Merit Medical (MMSI) Up 18.4% Since Last Earnings Report: Can It Continue?

Merit Medical Systems (MMSI) has registered an increase in revenues at both its key operating segments in Q1

Merit Medical (MMSI) Tops Q1 Earnings and Revenue Estimates

Merit Medical Systems, Inc. (MMSI) CEO Fred Lampropoulos on Q1 2020 Results - Earnings Call Transcript

SOUTH JORDAN, Utah, April  20, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, announced today that it has commenced production of a sample collection and transport kit, comprised of a nasopharyngeal swab and transport vial, used to collect specimens with suspected presence of Coronavirus Disease 2019 (COVID-19). The kit will be produced at Merit’s facility in South Jordan, Utah, with other Utah companies providing various services.

MERIT MEDICAL SYSTEMS DESIGNS AND PRODUCES SAMPLE COLLECTION AND TRANSPORT KIT

CONMED

MMSI vs. CNMD: Which Stock Is the Better Value Option?

This regulatory clearance is expected to bolster Merit Medical Systems' (MMSI) cardiovascular segment.

Merit Medical WRAPSODY Gets 2 FDA Breakthrough Device Nods

SOUTH JORDAN, Utah, April  06, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has been granted two additional Breakthrough Device designations by the U.S. Food and Drug Administration (FDA) for the Merit WRAPSODY™ Endovascular Stent Graft System. The WRAPSODY system is a flexible, self-expanding endoprosthesis.

MERIT MEDICAL RECEIVES TWO ADDITIONAL FDA BREAKTHROUGH DEVICE DESIGNATIONS

*Core revenue is a non-GAAP financial measure. A reconciliation of core revenue to GAAP revenue is included under the heading “Non-GAAP Financial Measures” below.

MERIT MEDICAL PROVIDES HISTORICAL REVENUES IN REVISED PRESENTATION FORMAT

Merit Medical (MMSI) Down 24.4% Since Last Earnings Report: Can It Rebound?

SOUTH JORDAN, Utah, March  18, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it experienced an early morning earthquake of 5.7 magnitude.

Merit Medical Response to Earthquake in Salt Lake City

Masimo

Teva Pharmaceutical

Welltower

With a world that is very concerned over the spread of the coronavirus, health care stocks, especially the top pharmaceutical stocks, have been in the spotlight as researchers scurry to find a cure.

Raymond James Makes Huge Changes To Healthcare Top Picks List

Merit Medical's (MMSI) fourth-quarter results gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.

Merit Medical (MMSI) Q4 Earnings & Revenues Beat Estimates

Merit Medical Systems, Inc. (MMSI) CEO Fred Lampropoulos on Q4 2019 Results - Earnings Call Transcript

Merit Medical (MMSI) delivered earnings and revenue surprises of 17.65% and 2.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Tops Q4 Earnings and Revenue Estimates

SOUTH JORDAN, Utah, Feb.  20, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, announced today that regulatory clearances have been issued with respect to four products Merit owns or holds the rights to distribute.

Merit Medical Systems Announces Four Regulatory Approvals

SOUTH JORDAN, Utah, Jan.  27, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today confirmed that it has received notice from Starboard Value LP (“Starboard”) that it has nominated seven individuals to stand for election as directors at Merit’s 2020 Annual Meeting of Shareholders (the “Annual Meeting”). In its notice to Merit, Starboard indicated that it intends to withdraw four of its seven nominees if there are only three seats on Merit’s Board to be filled at the Annual Meeting. The date of the Annual Meeting has not yet been set.

Merit Medical Issues Statement Regarding Director Nominations From Starboard

Merit Medical Systems, Inc.: A Buy Taking Patent Dynamics Into Account

SOUTH JORDAN, Utah, Nov.  21, 2019  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the Merit WRAPSODY™ Endovascular Stent Graft System. The WRAPSODY system is a flexible, self-expanding endoprosthesis for which Merit intends to seek indication for use in hemodialysis patients for the treatment of stenosis within the central veins of the outflow circuit of an arteriovenous fistula (AVF) up to the superior vena cava.

Merit Medical Receives FDA Breakthrough Device Designation for WRAPSODY™ Endovascular Stent Graft System

Some investors appeared to think that yesterday's sell-off was way overdone.

Why Merit Medical Systems Stock Soared Today

The medical device manufacturer had to lower forward-looking expectations -- again.

News for Merit Medical Systems Stock (MMSI)